# PharmaMar

a marine natural-products drug developer advancing clinical candidates including PM534 and PM742, which announced an AI collaboration with Globant in March 2026 aimed at accelerating oncology research with claimed 15x-faster insight generation and over 90% accuracy in its agentic research workflow.

Source: https://en.bioecon.ru/companies/pharmamar/
Updated: 2026-07-25

- Country: Spain

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Founded | 1986 | https://www.marketscreener.com/news/pharma-mar-s-a-non-financial-information-statement-consolidated-non-financial-information-stateme-ce7e5edddf8cf526 |
| Revenue | €221.39 million (FY 2025) | https://pharmamar.com/wp-content/uploads/2026/02/PR_PhM_Results_FY2025_final-1.pdf, https://pharmamar.com/wp-content/uploads/2026/03/PharmaMar_Corporate_Presentation_Marzo-_-web-1.pdf, https://www.marketscreener.com/news/pharma-mar-s-a-non-financial-information-statement-consolidated-non-financial-information-stateme-ce7e5edddf8cf526 |
| Headcount | 518 employees (as of end of 2025) | https://www.marketscreener.com/news/pharma-mar-s-a-non-financial-information-statement-consolidated-non-financial-information-stateme-ce7e5edddf8cf526 |
| Production site | Getafe, Madrid (oligonucleotide plant) | https://pharmamar.com/wp-content/uploads/2025/02/INFORME-DICIEMBRE-2024-ENG.pdf, https://pharmamar.com/wp-content/uploads/2025/12/PR_Sylentis_obtains_Good_Manufacturing_Practices_certification_from_the_EMA_for_its_new_plant.pdf |
| Certification | Good Manufacturing Practices (GMP) certification for oligonucleotide plant in Getafe (EMA/AEMPS) | https://pharmamar.com/wp-content/uploads/2025/02/INFORME-DICIEMBRE-2024-ENG.pdf, https://pharmamar.com/wp-content/uploads/2025/12/PR_Sylentis_obtains_Good_Manufacturing_Practices_certification_from_the_EMA_for_its_new_plant.pdf |
| Regulatory approval | FDA approval for Zepzelca in combination with Tecentriq (US, Oct 2025) | https://pharmamar.com/wp-content/uploads/2026/02/DICIEMBRE_2025_Informe-Anual-en-1.pdf, https://pharmamar.com/wp-content/uploads/2026/03/PharmaMar_Corporate_Presentation_Marzo-_-web-1.pdf, https://pharmamar.com/wp-content/uploads/2026/04/PR_PhM_Results_Q12026_final-1.pdf |
| Regulatory approval | Positive opinion from EMA recommending Zepzelca in combination with atezolizumab (EU, March 2026) | https://pharmamar.com/wp-content/uploads/2026/04/PR_PhM_Results_Q12026_final-1.pdf |
| Capacity | 3,800 m2 of production warehouse in Madrid designed for GMP standards [medium confidence] | https://www.conferenceharvester.com/uploads/harvester/exhibitors/3180/ABKLXTUJ-PDF-786536-632359-1-PDF.pdf |

Independent sources: conferenceharvester.com, marketscreener.com

## Technologies

- [Marine genomic prospecting & the BBNJ treaty](https://en.bioecon.ru/technology/marine-genomic-prospecting-bbnj-treaty/)